| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Ophthalmologic System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Ophthalmologic System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Ophthalmologic System |
Recent Updates
Recently added Catalysts
YD Bio Limited$2.3
+0.13 (+5.99%)
Market Cap
336.25 M
EPS
-
P/E Ratio
-
Value Trade
197.88 K
-11.38 %
Week
-9.87 %
1 Month
-46.02 %
3 Month
-43.18 %
6 Month
-52.64 %
5 Year
-70.31 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
142.89 K
52 Week Range
4.37 - 25
% held by Insiders
80.12 %
% held by Institutions
0.23 %
Enterprise Value
330.25 M
Total Shares
70.82 M
Short %
0.18 %
Float Shares
14.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for YD Bio Limited
3Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
▲Other Regulator MilestoneEx-US Regulatory
Subscribe to view catalyst details
TBD
▲Other Regulator MilestoneEx-US Regulatory
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in YDES
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
YDES Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
YDES▲ +6%today
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
YD Bio Limited has highlighted a peer-reviewed study published in Bioengineering that introduces a new computational framework aimed at identifying regenerative targets for keratoconus. The study, co-authored with Taipei Medical University, emphasizes a data-driven approach to analyze genetic data related to corneal disease. This research aims to address the unmet need for effective regenerative therapies for keratoconus.
Read more →YDES▲ +6%today
YD Bio 發表圓錐角膜研究新成果，與台北醫學大學攜手建立再生療法科學基礎
YD Bio Limited has announced a new collaborative research study with Taipei Medical University (TMU) focusing on corneal diseases. This research, published in the journal Bioengineering, aims to improve diagnostic methods using advanced data analysis techniques. The collaboration highlights the potential for significant advancements in understanding and treating corneal diseases.
Read more →YDESYD Bio 與 Numia Health 啟動跨境癌症檢測試辦計畫，評估拓展加拿大分子診斷服務之可行性
YD Bio and Numia Health have initiated a pilot program to enhance access to cancer diagnostics across borders. This collaboration focuses on developing a testing framework that supports patients in Canada, particularly in the Lower Mainland area. The program aims to streamline the testing process for various cancers using advanced molecular diagnostics. The pilot is set to begin in six months, with expectations for significant patient engagement.
Read more →YDESYD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
YD Bio Limited has launched a six-month pilot collaboration with Numia Health to evaluate the scalability of blood-based cancer testing in Canada. The pilot aims to establish a cross-border clinical workflow for physician-ordered tests, focusing on various cancer types. This initiative represents YD Bio's first structured clinical-access effort in Canada, reflecting its strategy to enhance patient access to advanced diagnostics.
Read more →YDES▲ +9.8%on this newsshared move
YD Bio 攜手愛立基生醫圓滿完成 2026 亞洲生技大展展出，展示眼科、腫瘤診斷與臨床服務領域創新成果
YD Bio Limited has announced the successful completion of its collaboration with EG BioMed, showcasing advancements in biotechnology at the BIO Asia-Taiwan 2026 event. The company is focusing on expanding its market presence in the U.S. with innovative products such as Exovisse™. Future clinical trials are planned for 2026, indicating a strong pipeline for the company.
Read more →YDES▼ -7.7%on this newsshared move
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
YD Bio Limited and EG BioMed concluded a successful exhibition at BIO Asia-Taiwan 2026, showcasing innovations in ophthalmology and oncology diagnostics. The companies presented their advancements, including preservative-free artificial tears and DNA-based cancer detection technologies. They engaged with over 30 prospective partners, demonstrating strong interest in their integrated healthcare approach and services for U.S. market entry.
Read more →YDES永鼎醫藥美國實驗室服務版圖擴展至46州，強化DNA甲基化早期癌症檢測業務
EG BioMed US Inc. has announced the expansion of its laboratory services across 46 states, focusing on DNA-based early-stage cancer testing. The company has received CLIA and CAP certifications, allowing it to enhance its diagnostic capabilities. This expansion aims to improve access to advanced cancer testing services and support the growing demand for such diagnostics in the U.S.
Read more →YDESYD Bio Expands U.S. Laboratory Footprint to 47 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio's affiliate, EG BioMed US, has expanded its laboratory operations to 47 U.S. states by obtaining clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion enhances patient access to early cancer detection services through their CLIA-certified laboratory. The company emphasizes the importance of real-world molecular data in validating its diagnostic capabilities, while also pursuing a merger with EG BioMed, which remains subject to regulatory conditions.
Read more →YDES▼ -17.7%on this newsshared move
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited has expanded its laboratory operations to 46 U.S. states by obtaining clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion enhances patient access to early cancer detection services through its accredited laboratory and telehealth platform. The company views this growth as a critical step in accumulating high-quality molecular data for cancer diagnostics.
Read more →YDESYD Bio Limited Reports Full Year 2025 Financial Results
YD Bio Limited reported a transformative year in 2025, achieving a 17% increase in net revenue, primarily from pharmaceutical sales. The company strengthened its financial position through a business combination and a PIPE financing. Despite a rise in net loss to $8.3 million, YD Bio is focused on advancing its therapeutics pipeline and expanding its healthcare platform in 2026.
Read more →YDESYD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio Limited has announced a strategic partnership with YC Biotech Co., Ltd. to create a Taiwan-U.S. dual-core regulatory platform. This collaboration will streamline FDA-related projects, including IND, NDA, and BLA submissions. YD Bio USA will act as YC Biotech's exclusive U.S. agent, enhancing regulatory navigation for clients. The partnership aims to expand services and strengthen YD Bio's position in the U.S. regulatory landscape.
Read more →YDES▼ -9.9%on this news
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Limited has signed a binding Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., enhancing its position in advanced immunocell therapy. This acquisition aims to integrate SSMC's proprietary technology into YD Bio's portfolio, focusing on personalized cancer treatments. The deal is valued at approximately NT$839.83 million and is expected to close within 30 days after due diligence.
Read more →YDESYDES 1 YD Bio Limited: Architecting the Modern Biotechnology Ecosystem Investment Deck January 2026 Forward - looking Statements 2 This presentation contains forward - looking statements within the meaning of the safe ha
YD Bio Limited has presented an investment deck outlining its strategic vision for creating a modern biotechnology ecosystem. The company plans to leverage partnerships and technology integration to enhance its operational capabilities and market position. They emphasize a disciplined U.S. expansion while addressing potential risks associated with its forward-looking statements. The focus for 2026 includes strengthening clinical evidence generation and considering strategic acquisitions to support platform capabilities.
Read more →YDES▲ +5.7%on this news
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
YD Bio Limited has announced significant milestones in its clinical and commercial roadmap for 2026, focusing on stem cell therapy and early cancer detection technologies. The company has completed critical CMC activities and filed Drug Master Files with the FDA, aiming to transition to accelerated clinical development. Despite the positive advancements, regulatory approvals and the success of future acquisitions remain uncertain.
Read more →YDESYD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
YD Bio Limited has expanded its OkaiDx testing platform to include pancreatic and colorectal cancer detection across the U.S. The company reported promising clinical data showing high sensitivity and specificity for early-stage pancreatic cancer detection. Access to these tests is facilitated through a telehealth network and partnerships with medical groups, although the tests are not yet FDA approved.
Read more →YDES▲ +7.8%on this news
INDEX TO FINANCIAL STATEMENTS YD BIO LIMITED Unaudited Interim Financial Statements Page Condensed Consolidated Balance Sheet as of
YD Bio Limited has released its unaudited interim financial statements for the period ending June 30, 2025. The company reported a net loss of $1,239 with total liabilities and shareholder's deficit amounting to $67,680. Since its inception in February 2024, YD Bio Limited has not yet generated any revenue and continues to face financial challenges. Following a merger, the company has restructured its shareholding but remains in a deficit position.
Read more →Competitive Position
How YDES ranks across every disease it competes inCompetitive Position is a premium feature
See how YDES ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial